The treatment of Parkinson's disease (PD) has for over 50 years relied on dopaminergic
therapies that are highly effective especially in the early years of the condition, but ultimately are …

Recent reports demonstrate that somatic mouse cells can be directly converted to other mature
cell types by using combined expression of defined factors. Here we show that the same …

Stem cell treatments for neurodegenerative diseases are expected to reach clinical trials soon.
Most of the approaches currently under development involve transplantation of immature …

Human pluripotent stem cells possess the potential to generate cells for regenerative therapies
in patients with neurodegenerative diseases, and constitute an excellent cell source for …

Stem cell engineering and grafting of mesencephalic dopamine (mesDA) neurons is a
promising strategy for brain repair in Parkinson's disease (PD). Refinement of differentiation …

To model human neural-cell-fate specification and to provide cells for regenerative therapies,
we have developed a method to generate human neural progenitors and neurons from …

Considerable progress has been made in generating fully functional and transplantable
dopamine neurons from human embryonic stem cells (hESCs). Before these cells can be used …

Generation of precisely patterned neural cells from human pluripotent stem cells (hPSCs) is
instrumental in developing disease models and stem cell therapies. Here, we provide a …

The study of brain development in humans is limited by the lack of tissue samples and
suitable in vitro models. Here, we model early human neural tube development using human …

Cell replacement therapies for Parkinson's disease (PD) based on transplantation of
pluripotent stem cell-derived dopaminergic neurons are now entering clinical trials. Here, we …